Hold
EnTruda is placed directly into a reachable solid tumor. It is developed to hold there.
INJECT THE TUMOR. KILL THE CANCER.
EnTruda is physician-directed therapy placed directly into a reachable solid tumor. It is developed to hold there, break the tumor down from within over 48 to 72 hours, and call your immune system into the work — 1) without chemo throughout the body, 2) surgery, or 3) radiation.
The initial physician review is free. Send the latest scans and reports. An ICCA physician says plainly whether EnTruda belongs in the plan. First treatments open November 1, 2026. The review starts now.
Learn more about EnTruda and its physician-directed approach to treating solid tumors.
Have questions about whether EnTruda may be appropriate for you? Our medical team can review your case.
EnTruda is physician-directed therapy placed directly into a reachable solid tumor. It is developed to hold there, break the tumor down from within over 48 to 72 hours, and call your immune system into the work.
EnTruda is meant for solid tumors a physician can reach with a needle under image guidance (e.g. ultrasound, CT or MRI if indicated).
EnTruda is placed directly into a reachable solid tumor. It is developed to hold there.
It is developed to break the tumor down from within over 48 to 72 hours.
It is developed to call your immune system into the work.
Two treatment days: Day 1 and Day 14. Days 2–13 are the cell-building days.
Labs, baseline CT, blood draw for T cells, treatment into the tumor, home the same afternoon.
Those T cells are grown in ICCA’s GMP lab. The patient is home.
Activated T cells and a second NK-cell dose by IV. EnTruda into the entire tumor. Home the same day.
EnTruda is developed to spread through the tumor and break it down from within.
This is an example. An ICCA physician sets each patient’s plan.
Treatment is placed into the tumor itself.
Placed with a needle, under image guidance.
The plan does not use radiation.
Outpatient. Home the same day on Day 1 and Day 14.
Results vary from patient to patient. Side effects can occur, and your physician will review them with you before treatment.
An ICCA physician decides whether EnTruda belongs in the plan. These are the first things the physician looks at.
Six quick fields. The ICCA care team calls you back.
The initial physician review is free. Send the latest scans and reports. An ICCA physician says plainly whether EnTruda belongs in the plan.

The initial physician review is free. Send the latest scans and reports.